Effects of flunixin meglumine, phenylbutazone and a selective thromboxane synthetase inhibitor (UK-38,485) on thromboxane and prostacyclin production in healthy horses.
The efficacy of three agents which alter the metabolism of arachidonic acid was investigated in normal, conscious horses. A dose response evaluation was made of flunixin meglumine and phenylbutazone, two cyclo-oxygenase inhibitors, and of a selective thromboxane synthetase inhibitor, UK-38,485. Radioimmunoassay of thromboxane B2 (TxB2) and 6-keto prostaglandin F1 alpha (PGF1 alpha) was used to assess the concentrations of thromboxane A2 (TxA2) and prostacyclin (PGI2) respectively, in serum. Flunixin was the most potent inhibitor of serum TxB2 and 6-keto PGF1 alpha production. UK-38,485 also decreased serum TxB2 generation while significantly increasing serum 6-keto PGF1 alpha levels, thus confirming its selectivity as a thromboxane synthetase inhibitor.
D015121:6-Ketoprostaglandin F1 alpha / Q000096:biosynthesis / Q000097:blood; D000818:Animals; D003002:Clonixin / Q000008:administration & dosage / Q000031:analogs & derivatives / Q000494:pharmacology*; D011464:Epoprostenol / Q000096:biosynthesis* / Q000097:blood; D006736:Horses / Q000378:metabolism*; D007093:Imidazoles / Q000008:administration & dosage / Q000494:pharmacology*; D008297:Male; D009539:Nicotinic Acids / Q000494:pharmacology*; D009919:Orchiectomy; D010653:Phenylbutazone / Q000008:administration & dosage / Q000494:pharmacology*; D013928:Thromboxane A2 / Q000097:blood; D013929:Thromboxane B2 / Q000096:biosynthesis* / Q000097:blood; D013930:Thromboxane-A Synthase / Q000008:administration & dosage / Q000037:antagonists & inhibitors
D007093:Imidazoles; D009539:Nicotinic Acids; C039242:dazmegrel; D013929:Thromboxane B2; D013928:Thromboxane A2; D015121:6-Ketoprostaglandin F1 alpha; C014558:flunixin meglumine; D011464:Epoprostenol; D013930:Thromboxane-A Synthase; D010653:Phenylbutazone; D003002:Clonixin